Suggested remit: To appraise the clinical and cost effectiveness of trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6651
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators:
- 24 February 2026 - 24 March 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 February 2026 | In progress. Scoping commenced. |
| 01 December 2025 - 01 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 November 2025 | Please note the appraisal is due to start in mid-May 2026. Submissions are expected in mid-July 2026. |
| 09 October 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual